anti-PD-L1/TGF-beta bispecific antibody Y101D

A recombinant bispecific antibody targeting both the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and the human transforming growth factor beta (TGF-beta), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, the anti-PD-L1/TGF-beta bispecific antibody Y101D targets, binds to and neutralizes TGFbeta while simultaneously targets, binds to, and inhibits the activity of PD-L1 on tumor cells. This prevents both TGF-beta- and PD-L1-mediated immuno-suppressive pathways signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This restores and enhances anti-tumor responses and inhibits tumor cell proliferation in susceptible tumor cells. TGF-beta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.